Figure 4 - available via license: Creative Commons Attribution-NonCommercial 4.0 International
Content may be subject to copyright.
Intravenous psilocybin dose-dependently disrupted theta-gamma coupling. Following psilocybin infusion, both the 1 mg/kg and 10 mg/kg doses resulted in decoupling of theta phase from medium (A) and high (B) gamma amplitudes in a dose-dependent fashion. PAC was not altered by the 0.1 mg/kg dose. Each grid represents a 10-minute average of PAC values across all rats (n=12). Each square indicates an electrode in the layout described in Figure 1. White and black asterisks: p<0.05, FDR-corrected post-hoc comparisons.
Source publication
Psilocybin produces an altered state of consciousness in humans and is associated with complex spatiotemporal changes in brain networks. Given the emphasis on rodent models for mechanistic studies, there is a need for characterization of the effect of psilocybin on brain-wide network dynamics. Previous rodent studies of psychedelics, using electroe...
Contexts in source publication
Context 1
... compared to saline infusion, 0.1 mg/kg psilocybin did not produce any statistically significant changes in either theta-medium gamma or theta-high gamma PAC (p>0.05; Figure 4). In contrast, both 1 mg/kg and 10 mg/kg psilocybin infusion diminished theta-medium gamma PAC across the entire Figure 4A). ...
Context 2
... compared to saline infusion, 0.1 mg/kg psilocybin did not produce any statistically significant changes in either theta-medium gamma or theta-high gamma PAC (p>0.05; Figure 4). In contrast, both 1 mg/kg and 10 mg/kg psilocybin infusion diminished theta-medium gamma PAC across the entire Figure 4A). After 20 minutes of 1 mg/kg infusion, there was a decrease in theta-medium gamma PAC in the extreme frontal (p≤0.047) and posterior/occipital areas (p≤0.049), ...
Context 3
... PAC values started to recover back to saline values after the cessation of psilocybin infusion but remained significantly low at the end of 20 minutes post-psilocybin period (p≤0.038). The effect of 10 mg/kg psilocybin on theta-medium gamma PAC ( Figure 4A) was similar, but the onset time was faster (10 minutes after 10 mg/kg vs 20 minutes after 1 mg/kg psilocybin). ...
Context 4
... theta-high gamma PAC (Figure 4B) was only mildly affected by 1 mg/kg of psilocybin and with late onset (after 40 minutes of infusion). The decrease was restricted primarily to the frontal regions (p<0.050), which returned to saline values within 10 minutes after cessation of psilocybin infusion. ...
Context 5
... decrease was restricted primarily to the frontal regions (p<0.050), which returned to saline values within 10 minutes after cessation of psilocybin infusion. The 10 mg/kg dose of psilocybin showed a much stronger effect on theta-high gamma PAC, which showed wide-spread decreases across the cortex after 10 minutes of infusion (p≤0.048) and which remained significantly low through the post-infusion period ( Figure 4B). In summary, psilocybin infusion dose-dependently disrupted local thetagamma coupling across the cortex, but particularly in frontal cortex, potentially dysregulating information coordination. ...
Similar publications
Rationale
Psilocybin shows promise for treating neuropsychiatric disorders. However, insight into its acute effects on cognition is lacking. Given the significant role of executive functions in daily life and treatment efficacy, it is crucial to evaluate how psilocybin influences these cognitive domains.
Objectives
This meta-analysis aims to quant...
Background Anxiety disorders are increasingly prevalent among young adults. Traditional treatment options often fall short, and many patients live with treatment-resistant anxiety. Psilocybin is a psychedelic compound that has gained attention for its therapeutic potential against anxiety when used in microdoses. Objective This review aims to evalu...
Recent research with classic psychedelics suggests significant therapeutic potential, particularly for neuropsychiatric disorders. A mediating influence behind symptom resolution is thought to be the personal insight – at times, bordering on the mystical – one acquires during the acute phase of a psychedelic session. Indeed, current clinical trials...
A variety of classic psychedelics and MDMA have been shown to enhance fear extinction in rodent models. This has translational significance because a standard treatment for posttraumatic stress disorder (PTSD) is prolonged exposure therapy. However, few studies have investigated psilocybin's potential effect in fear learning paradigms. More specifi...
Background
Psychedelic assisted psychotherapy (PAP) can improve treatment-resistant depression. Its usefulness in Parkinson's disease (PD) is unknown. PD patients may have problems adjusting to their chronic progressive neurological disease. A change from emotional avoidance to acceptance has been reported following psilocybin administration in pat...
Citations
... In our study, we decided to focus on the prefrontal cortex, as this brain region appears to be significantly affected by psilocybin treatment in humans (Carhart-Harris et al. 2012). Recent findings also reveal that PSI significantly affects network organization in the rat cortex (Silverstein et al. 2024). On molecular level, it has been shown that PSI induces a sustained increase in dendritic spines in the frontal cortex, which may impact the brain's adaptive capacity (Shao et al. 2021). ...
Rationale
Our study aimed to unravel the unknown mechanisms behind the exceptional efficacy of Psilocybin (PSI) in treating treatment-resistant depression (TRD). Focusing on Wistar-Kyoto (WKY) rats with a TRD phenotype and Wistar (WIS) rats as a normative comparison, we investigated behavioral and neuroplasticity-related responses to PSI, striving to shed light on the distinctive features of its antidepressant effects.
Objectives
We set out to assess the behavioral impact of acute and prolonged PSI administration on WKY and WIS rats, employing Novel Object Recognition (NORT), Social Interaction (SI), and Forced Swimming Test (FST). Our secondary objectives involved exploring strain-specific alterations in neuroplasticity-related parameters, including brain-derived neurotrophic factor (BDNF) and activity-regulated cytoskeleton-associated protein (Arc).
Methods
Conducting post-acute and extended assessments after a single PSI administration, we applied behavioral tests and biochemical analyses to measure serum BDNF levels and neuroplasticity-related parameters in the prefrontal cortex. Statistical analyses were deployed to discern significant differences between the rat strains and assess the impact of PSI on behavioral and biochemical outcomes.
Results
Our findings uncovered significant behavioral disparities between WKY and WIS rats, indicating passive behavior and social withdrawal in the former. PSI demonstrated pronounced pro-social and antidepressant effects in both strains, each with its distinctive temporal trajectory. Notably, we identified strain-specific variations in BDNF-related signaling and observed the modulation of Arc expression in WKY rats.
Conclusions
Our study delineated mood-related behavioral nuances between WKY and WIS rat strains, underscoring the antidepressant and pro-social properties of PSI in both groups. The distinct temporal patterns of observed changes and the identified strain-specific neuroplasticity alterations provide valuable insights into the TRD phenotype and the mechanisms underpinning the efficacy of PSI.